Clinical responses and adverse events on forodesine therapy (n = 7)
| . | Value . |
|---|---|
| Median therapy duration, wk (range) | 8.7 (4-20) |
| Median no. of therapy cycles (range) | 2 (1-4) |
| Decrease in ALC to normal, n (%) | 2 (29) |
| Progressive increase in ALC, n (%) | 5 (71) |
| Lymphadenopathy progression, n (%) | 3 (43) |
| Adverse event (all grades), n (%) | |
| Fatigue | 3 (43) |
| Bronchitis | 3 (43) |
| Diarrhea, mucositis | 2 (29) |
| Fever, low-grade | 3 (43) |
| Transient neutropenia and/or thrombocytopenia | 3 (43) |
| Pneumonia | 1 (14) |
| . | Value . |
|---|---|
| Median therapy duration, wk (range) | 8.7 (4-20) |
| Median no. of therapy cycles (range) | 2 (1-4) |
| Decrease in ALC to normal, n (%) | 2 (29) |
| Progressive increase in ALC, n (%) | 5 (71) |
| Lymphadenopathy progression, n (%) | 3 (43) |
| Adverse event (all grades), n (%) | |
| Fatigue | 3 (43) |
| Bronchitis | 3 (43) |
| Diarrhea, mucositis | 2 (29) |
| Fever, low-grade | 3 (43) |
| Transient neutropenia and/or thrombocytopenia | 3 (43) |
| Pneumonia | 1 (14) |
ALC indicates absolute lymphocyte count.